EGFR and neoplasm: Hyperactivation of epidermal growth factor receptor (EGFR) signaling is a critical contributor for the development and progression of lung cancer [163]; therefore, TKIs are widely applied to treat non-small cell lung cancer (NSCLC) with the hyperactivation of EGFR signaling; however, some tumours will finally develop acquired resistance to TKIs.